{"title":"口腔念珠菌病治疗的实用更新。","authors":"Dina Zamil, Theodore Rosen","doi":"10.36849/jdd.8481","DOIUrl":null,"url":null,"abstract":"<p><p>Dermatologists are likely to periodically encounter candidiasis in clinical practice, especially given the increased risk with the use of new broad-spectrum IL-17 blocking psoriasis agents such as bimekizumab. Oral candidiasis may be white or red, classically presenting as cottage-cheese consistency plaques associated with symptoms of a burning mouth and dysgeusia. Standard first- and second-line antifungal medications can easily and safely be prescribed by dermatologists. In this article, we summarize clinical presentations and treatment algorithms for oral candidiasis relevant to the dermatologist. We also present indications and criteria for infectious disease referral or hospitalization. J Drugs Dermatol. 2024;23(12):e186-e190. doi:10.36849/JDD.8481e.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 12","pages":"e186-e190"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Practical Update on Treatment of Oral Candidiasis.\",\"authors\":\"Dina Zamil, Theodore Rosen\",\"doi\":\"10.36849/jdd.8481\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dermatologists are likely to periodically encounter candidiasis in clinical practice, especially given the increased risk with the use of new broad-spectrum IL-17 blocking psoriasis agents such as bimekizumab. Oral candidiasis may be white or red, classically presenting as cottage-cheese consistency plaques associated with symptoms of a burning mouth and dysgeusia. Standard first- and second-line antifungal medications can easily and safely be prescribed by dermatologists. In this article, we summarize clinical presentations and treatment algorithms for oral candidiasis relevant to the dermatologist. We also present indications and criteria for infectious disease referral or hospitalization. J Drugs Dermatol. 2024;23(12):e186-e190. doi:10.36849/JDD.8481e.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"23 12\",\"pages\":\"e186-e190\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/jdd.8481\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/jdd.8481","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Practical Update on Treatment of Oral Candidiasis.
Dermatologists are likely to periodically encounter candidiasis in clinical practice, especially given the increased risk with the use of new broad-spectrum IL-17 blocking psoriasis agents such as bimekizumab. Oral candidiasis may be white or red, classically presenting as cottage-cheese consistency plaques associated with symptoms of a burning mouth and dysgeusia. Standard first- and second-line antifungal medications can easily and safely be prescribed by dermatologists. In this article, we summarize clinical presentations and treatment algorithms for oral candidiasis relevant to the dermatologist. We also present indications and criteria for infectious disease referral or hospitalization. J Drugs Dermatol. 2024;23(12):e186-e190. doi:10.36849/JDD.8481e.
期刊介绍:
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.